Penn Vet | Cancer Clinical Trial - Clinical evaluation of propranolol and doxorubicin for the treatment of splenic hemangiosarcoma in the dog
Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Clinical evaluation of propranolol and doxorubicin for the treatment of splenic hemangiosarcoma in the dog

Aug 16, 2019

The purpose of this study is to determine whether propranolol in combination with standard of care doxorubicin chemotherapy can improve outcomes for dogs with hemangiosarcoma. Propranolol is currently used as a blood pressure medication. Dogs in this study will be treated with standard of care chemotherapy (doxorubicin). Each of the dogs will be randomly chosen to receive one of three different doses of propranolol concurrently with the chemotherapy. Dogs enrolled in this study will have doxorubicin therapy once every 3 weeks for 5 treatments, followed by follow-up visits every 3 months until one year from start of chemotherapy.

Eligibility:

  • Hemangiosarcoma restricted to the spleen, which has been treated with surgical removal prior to study
  • No evidence of metastatic disease
  • Weighing at least 15 kgs (33 pounds)
  • Have an adequate supply of red blood cells (>/= 22% packed cell volume)
  • Not currently undergoing treatment for cancer including chemotherapy or alternative/holistic medications or supplements
  • No other significant health concerns that are an immediate threat to life (including but not limited to kidney, liver, or heart disease, or problems with blood clotting)
  • Ability to administer oral medication (pills) to your dog.

 
Please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu for more information about this study.